Lee W Y, Sehon A H
J Immunol. 1976 Sep;117(3):927-34.
Reaginic antibodies to the benzylpenicilloyl determinant (BPO) and ovalbumin (OA) were induced readily in B6D2F1 mice by a single i.p. injection of either 1 or 10 mug of BPO4-OA suspended with 1 mg of Al(OH)3 in 0.5 ml of saline. Administration of conjugates consisting of the hapten coupled to the isologous, nonimmunogenic murine gamma-globulins (MgammaG), i.e., BPO9-MgammaG, BPO11-MgammaG, or BPO12-MgammaG, resulted in complete and specific suppression of the induction of the anti-BPO reaginic antibody response without affecting, however, the level of reaginic antibodies to OA. Further study of the effect of epitope density on the immunologic properties of BPOX-MgammaG revealed that a) the lightly haptenated conjugated, BPO1-MgammaG and BPO2.9-MgammaG, were not immunosuppressive, b) the conjugates, BPO4.3-MgammaG and BPO19-MgammaG, were partially tolerogenic, and c) the heavily haptenated conjugate, BPO31-MgammaG, was nontolerogenic. Moreover, most importantly, the ongoing anti-BPO response in sensitized mice was readily abrogated by either four daily or four weekly injections of BPO9-MgammaG. The immunosuppressive effect of BPO12-MgammaG conjugates was dose dependent, complete suppression being achieved with 200 mug of the tolerogen. The unresponsiveness to BPO of spleen cells from immunosuppressed donors was also maintained in adoptive cell transfer experiments in spite of the additional administration of the immunizing antigen under conditions expected to yield a secondary IgE response. Hence, it is suggested that, with special precautions to prevent unleashing an anaphylactic shock, treatment of penicillin-sensitive individuals with polyvalent conjugates of an appropriate number of BPO groups per human gamma-globulin molecule would constitute a rational immunotherapeutic procedure for the abrogation of the allergic response to BPO.
通过在0.5毫升盐水中将1或10微克的BPO4 - OA与1毫克氢氧化铝悬浮后单次腹腔注射,可在B6D2F1小鼠中轻易诱导出针对苄青霉素酰基决定簇(BPO)和卵清蛋白(OA)的反应素抗体。给予由半抗原与同源、无免疫原性的鼠γ球蛋白(MγG)偶联而成的缀合物,即BPO9 - MγG、BPO11 - MγG或BPO12 - MγG,可完全且特异性地抑制抗BPO反应素抗体反应的诱导,然而,却不影响针对OA的反应素抗体水平。对表位密度对BPOX - MγG免疫特性影响的进一步研究表明:a)轻度半抗原化的缀合物BPO1 - MγG和BPO2.9 - MγG无免疫抑制作用;b)缀合物BPO4.3 - MγG和BPO19 - MγG具有部分耐受性;c)高度半抗原化的缀合物BPO31 - MγG无耐受性。此外,最重要的是,致敏小鼠中正在进行的抗BPO反应可通过每日注射四次或每周注射四次BPO9 - MγG轻易消除。BPO12 - MγG缀合物的免疫抑制作用呈剂量依赖性,2百微克的耐受原可实现完全抑制。在过继性细胞转移实验中,尽管在预期会产生二次IgE反应的条件下额外给予了免疫抗原,但免疫抑制供体的脾细胞对BPO的无反应性仍得以维持。因此,有人提出,在采取特殊预防措施以防止引发过敏性休克的情况下,用人γ球蛋白分子上具有适当数量BPO基团的多价缀合物治疗青霉素敏感个体,将构成一种消除对BPO过敏反应的合理免疫治疗方法。